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The angiotensin AT4 receptor was originally defined as the specific, high affinity binding site for the hexa- 
peptide angiotensin IV (Ang IV). Subsequently, the peptide LVV-hemorphin 7 was also demonstrated to be a 
bioactive ligand of the AT4 receptor. Central administration of Ang IV or LVV-hemorphin 7 (LVV-H7) markedly 
enhances learning and memory in normal rodents and reverse memory deficits observed in animal models of am- 
nesia. The high affinity binding site has a broad distribution in the brain including areas such as the hippocma- 
pus that are involved in memory processing. The high affinity Ang IV binding site (AT4 receptor) has been identi- 
fied as the transmembrane enzyme, insulin-regulated membrane aminopeptidase (IRAP). Insulin-regulated 
aminopeptidase is a type II integral membrane spanning protein belonging to the M1 family of aminopeptidases 
and in insulin-responsive cells colocalizes with GLUT4 in specific intra-cellular vesicles. Both Ang IV and LVV- 
H7 are competitive inhibitors of IRAP catalytic activity and are not substrates of the enzyme. 
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1. MEMORY LOSS 
 
Alzheimer’s disease is an age-related impairment in cogni- 
tion and memory. It is the most common type of dementia 
occurring in later life, affecting 10% of individuals over 65 
years of age. The prevalence of this disease is underscored by 
the prediction that by the year 2050 approximately one quar- 
ter of the population will be over 65 years of age.1) A delay in 
the onset of debilitating symptoms will allow people with 
Alzheimer’s disease to continue functioning independently 
for longer periods.1) For example a delay of five years for all 
age groups over age 65 would potentially reduce nearly half 
the number of individuals with the disease. 
In addition, memory loss occurs not only in Alzheimer’s 
disease, but may also result from a range of other causes, in- 
cluding head trauma, hypoxic damage and multiple cerebral 
infarcts. Currently there is no effective treatment for memory 
loss in these conditions. The four prescription medications 
approved by the U.S. Food and Drug Administration (FDA) 
for the treatment of Alzheimer’s disease are all acetyl- 
cholinesterase inhibitors, which act to prevent the breakdown 
of the neurotransmitter acetylcholine. The effectiveness of 
this class of drugs is limited, showing only a modest im- 
provement in clinical trials and with more than half of the pa- 
tients showing no improvement. Other compounds that are 
still in the development stages include a novel AMPA recep- 
tor ligand and the natural extracts from the gingko plant. A 
new potential target for the development of drugs to treat 
memory loss is the M1 aminopeptidase, insulin-regulated 
aminopeptidase (IRAP). 
 
2. ANGIOTENSIN IV 
 
The connection between IRAP and memory has arisen 
from studies over the last decade on the renin angiotensin 
system (RAS) investigating the effect of the pentapeptide an- 
giotensin IV (Ang IV) on memory facilitation. The major bi- 
ologically active hormone of the RAS is angiotensin II (Ang 
II) with the 3—8 fragment of Ang II, Ang IV, originally con- 
sidered to be biologically inactive. However in 1989 Polish 
scientist Prof. J. J. Brasko demonstrated that an injection of 
Ang IV into the brain significantly enhanced memory in 
rats.2) Since this time a number of laboratories have demon- 
strated the ability of Ang IV to enhance memory in rats and 
mice.3—5) 
The most exciting component of this work has been within 
the last five years in which the ability of Ang IV to signifi- 
cantly improve memory in rats suffering from dementia has 
been demonstrated. Rats treated either surgically (bilateral 
perforant pathway knife cuts) or chemically (scopolamine 
hydrobromide) to induce amnesia are unable to perform sim- 
ple memory related tasks such as remembering the location 
of a hidden platform in swim mazes (Morris water maze) or 
avoiding areas in a two compartment chamber that emit 
weak, electric shocks (passive avoidance paradigm).4,6,7) Infu- 
sions of Ang IV into the brains of these rats enables them to 
successfully complete these simple behavioural tasks by re- 
versing their memory loss. Indeed after treatment, the mem- 
ory deficit rats can perform the memory, related tasks with 
similar efficacy as normal rats. 
In the brain, high affinity binding sites for Ang IV (previ- 
ously termed the AT4 receptor) have been mapped for a range 
of species, including humans, using radioligand binding.8—12) 
The distribution between species is consistent with high lev- 
els of radioligand binding observed in the motor nuclei and 
in areas associated with cognitive and sensorimotor func- 
tions, such as the hippocampus, neocortex and cerebellum. 
Of particular interest is the occurrence of high affinity bind- 
ing in areas associated with memory; areas of basal forebrain 
cholinergic nuclei, including the medial septal complex and 
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the basal nucleus of Meynert, and their terminal fields, such 
as the hippocampus and neocortex. In the hippocampus, Ang 
IV binding sites are present in the granular layer of the den- 
tate gyrus and the pyramidal cell layer of the CA1 to CA3 
fields of Ammon’s horn, regions containing cholinergic ter- 
minal fields derived from basal forebrain neurons. 
Release of the neurotransmitter, acetylcholine is well es- 
tablished as playing an important role in memory processing. 
Therefore based on the high levels of Ang IV binding sites in 
regions containing cholinergic bodies or their terminal fields 
in conjunction with the facilitory effect of Ang IV on mem- 
ory, the effect of Ang IV on acetylcholine release from hip- 
pocampal slices was investigated. Although Ang IV did not 
increase basal levels of acetylcholine release, it did increase 
depolarised induced release of acetylcholine from the hip- 
pocampus in a dose dependent manner.13) This suggests that 
potentiation of cholinergic transmission is one of the mecha- 
nisms by which Ang IV facilitates memory. In addition Ang 
IV has also been demonstrated to enhance long term potenti- 




In 1997 Chai and co-workers identified a second, distinct 
peptide that also bound with high affinity to the Ang IV bind- 
ing site the, alternative AT4 ligand, LVV-hemorphin-7 (LVV- 
H7).16) LVV-H7 was isolated from the sheep cerebral cortex, 
using a multi-step procedure of reverse-phase HPLC and ion- 
exchange chromatography based on its ability to compete 
with 125I-Ang IV for the high affinity Ang IV binding site. 
LVV-hemorphin-7 is the degradation product of the b -globin 
chain with identical sequence to the 30—39 residues of 
sheep b -globin chain, 32—41 of the human b -globin chain 
and residues 31—40 of bovine b -globin. This was the first 
indication that the system being investigated was not part of 
the RAS. It has subsequently been demonstrated that LVV- 
hemorphin-7 has the same effects both in vitro and in vivo as 
Ang IV. For example in vitro both cause modest increases in 
cellular proliferation in the SK-N-MC neuronal cell line, and 
both potentiate acetylcholine release in hippocampal 
slices.13,17) But the most important correlation is, that like 
Ang IV, LVV-H7 facilitates memory in both normal and 
scopolamine treated rats.18) Utilizing the Barnes circular 
maze, Ang IV and LVV-H7 were both demonstrated to facili- 
tate memory as assessed by mean number of days to reach 
learner criterion.18) In addition, like Ang IV, central adminis- 
tration of LVV-H7 attenuates the deleterious effects of scopol- 
amine on memory performance, observed in rats in the two 
different behavioral paradigms, the swim water maze and the 
passive aviodance task (Albiston et al., in press). 
 
4. IDENTIFICATION OF THE ANG IV BINDING SITE 
AS IRAP 
 
It was predicted that Ang IV mediated its effects via a spe- 
cific, seven transmembrane, G-protien coupled receptor. 
Therefore it was suprising when Harding and co-workers 
demonstrated that the high affinity Ang IV binding site was a 
single transmembrane protein of 165 kDa in size.19) Subse- 
quently our laboratory identified the high affinty Ang IV 
 
dase (IRAP).20) The Ang IV high affinity binding site was 
isolated from bovine adrenals by covalently crosslinking it 
with 125I-nle1-Ang IV followed by purification utilising anion 
exchange chromatography and gel electrophoresis. Peptide 
sequence obtained from a tryptic peptide by tandem mass 
spectrometry identified it as insulin-regulated aminopepti- 
dase (IRAP).20) Confirmation that the Ang IV binding site is 
IRAP has come through collation of a number of pharmaco- 
logical, biochemical and histological studies. IRAP like the 
high affinity Ang IV binding site is a single transmembrane 
glycoprotein 165 kDa in size. Cells transfected with the full- 
length cDNA for human IRAP gain expression of a high- 
affinity binding site for Ang IV with a pharmacological pro- 
file identical to the endogenous human AT4 receptor.20) Using 
competitive binding assays unlabelled AngIV and LVV-H7 
compete for [125I]Nle1-Ang IV binding to IRAP with IC50 
values of 32 and 140 nM respectively, values in agreement 
with those previously obtained for the AT4 receptor in the 
human neuronal cell line SK-N-MC.17,20) In addition the dis- 
tribution in the brain of both IRAP and the AT4 receptor is 
the same. The distribution of IRAP demonstrated by both im- 
munohistochemistry and in situ hybridisation histochemistry 
and the AT4 receptor distribution established by in vitro re- 
ceptor autoradiography. Recently utilizing the same ap- 
proaches we have also demonstrated parallel results in the 
mouse kidney. 
 
5. INSULIN-REGULATED AMINOPEPTIDASE 
 
IRAP is a member of the M1 family of aminopeptidases, 
which includes aminopeptidases A and N, and is classified 
based on the catalytic domain, containing the zinc-binding 
motif (HEXXHX18E) and the exopeptidase sequence 
(GXMEN).21,22) IRAP is a type II integral membrane protein 
and unique to the M1 aminopeptidase family contains a 109- 
amino acid cytoplasmic domain that is critical for the sub- 
cellular localization of the enzyme. The cytoplasmic domain 
contains two dileucine motifs and several acidic regions 
which are involved in vesicular trafficking.23) As a result, 
studies on the cytoplasmic amino terminus of IRAP have fo- 
cused on its role in trafficking, sorting and vesicle retention. 
IRAP has been identified by a number of laboratories in 
different contexts and has had a number of functions attrib- 
uted to it. As such, IRAP has been referred to in the literature 
as the AT4 receptor, cystyl-aminopeptidase, oxytocinase, va- 
sopressinase, gp160, placental leucine aminopeptidase (P- 
LAP) and vp165. A number of studies have investigated the 
potential substrates of IRAP and have demonstrated that in 
vitro IRAP is capable of cleaving oxytocin, vasopressin, Met- 
enkephalin, dynorphin A, Neurokinins A and B, somato- 
statin, CCK-8, and angiotensin III.24—27) However, the physi- 
ological substrate remains unknown. 
IRAP is a major protein present in intracellular vesicles 
containing the insulin dependent glucose transporter, 
GLUT4.28,29) In classic insulin responsive cells, such as 
adipocytes and muscle cells, IRAP has been demonstrated to 
translocate with GLUT4 to the plasma membrane following 
stimulation by insulin.29—31) In the brain the distribution of 
IRAP (described above) is similar to the localisation of 
GLUT4 as determined by both immunohistochemistry and 32,33) 
binding site (AT4  receptor) as insulin-regulated aminopepti- in-situ  hybridization. This  suggests  that  IRAP  in  the 
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brain may be present in neurons with GLUT4 in a system 
analogous to that present in classic insulin responsive tissues. 
Indeed we have recently demonstrated in both the rat and 
mouse hippocampus the colocalization of GLUT4 and IRAP 
in neurons at both the cellular and sub-cellular level (manu- 
script in preparation). 
 
6. AT4 LIGANDS (ANG IV AND LVV-H7) ARE IN- 
HIBITORS OF IRAP 
 
Using HEKT cells transiently transfected with human 
IRAP we have demonstrated that AT4 ligands inhibit the cat- 
alytic activity of IRAP (in vitro) as assessed by cleavage of 
the synthetic substrate Leu-b -naphthylamide.20,34) Both Ang 
IV and LVV-H7 display competitive kinetics indicating that 
AT4 ligands mediate their effects by binding to the catalytic 
site of IRAP.27) Using the same system we also have demon- 
strated that although the peptides Ang IV and LVV-H7 bind 
to the catalytic stie they are not cleaved by IRAP.27) 
Although IRAP was cloned nearly a decade ago, AT4 lig- 
ands are the first high affinity inhibitors of the enzyme to be 
identified. Development of stable, second generation in- 
hibitors of IRAP based on the AT4 ligands may provide the 
opportunity for the development of therapeutics for memory 
loss. In addition development of IRAP inhibitors is pivotal 
for the elucidation of how this interaction facilitates memory 
and also the role of IRAP aminopeptidase activity in insulin 
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